Claims data reveal larger hemoglobin A1c decreases in people with type 2 diabetes who use continuous glucose monitoring and semaglutide compared with semaglutide alone.
Peter M. Lynch, MPH
Advertisement
Articles by Peter M. Lynch, MPH
A retrospective claims analysis of managed care enrollees with type 2 diabetes mellitus showed that insulin pump therapy reduced antidiabetic drug and healthcare resource use.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Bepirovirsen Approval Offers New Option for Chronic HBV Treatment
2
Extension Studies in TPIP Show Promise in PAH, PH-ILD
3
Inhaled Amikacin Raises Culture Conversion in New MAC Lung Disease
4
Bronchiectasis GWAS Highlights Candidate Targets Shared With COPD
5